California Public Employees Retirement System lifted its stake in shares of Aimmune Therapeutics Inc (NASDAQ:AIMT) by 3.0% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 102,963 shares of the biotechnology company’s stock after purchasing an additional 2,960 shares during the quarter. California Public Employees Retirement System owned about 0.16% of Aimmune Therapeutics worth $1,721,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in the company. Zurcher Kantonalbank Zurich Cantonalbank raised its position in Aimmune Therapeutics by 125.9% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,895 shares of the biotechnology company’s stock worth $99,000 after acquiring an additional 3,286 shares in the last quarter. Morgan Stanley increased its position in shares of Aimmune Therapeutics by 84.4% in the first quarter. Morgan Stanley now owns 1,018,692 shares of the biotechnology company’s stock valued at $14,689,000 after buying an additional 466,231 shares in the last quarter. Raymond James Financial Services Advisors Inc. purchased a new position in shares of Aimmune Therapeutics in the second quarter valued at $173,000. Victory Capital Management Inc. increased its position in shares of Aimmune Therapeutics by 9.7% in the second quarter. Victory Capital Management Inc. now owns 2,070,531 shares of the biotechnology company’s stock valued at $34,598,000 after buying an additional 183,405 shares in the last quarter. Finally, Geode Capital Management LLC increased its position in shares of Aimmune Therapeutics by 8.9% in the first quarter. Geode Capital Management LLC now owns 657,657 shares of the biotechnology company’s stock valued at $9,482,000 after buying an additional 53,943 shares in the last quarter. Institutional investors and hedge funds own 74.47% of the company’s stock.

AIMT has been the subject of a number of research analyst reports. Credit Suisse Group raised their price target on Aimmune Therapeutics from $14.00 to $34.50 and gave the company a “neutral” rating in a research report on Tuesday, September 1st. BidaskClub cut Aimmune Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Friday, July 10th. Piper Sandler cut Aimmune Therapeutics from an “overweight” rating to a “neutral” rating and dropped their price target for the company from $60.00 to $34.50 in a research report on Monday, August 31st. Stifel Nicolaus reaffirmed a “hold” rating and set a $18.00 price objective on shares of Aimmune Therapeutics in a research note on Thursday, July 30th. Finally, Cantor Fitzgerald lowered Aimmune Therapeutics from an “overweight” rating to a “neutral” rating and increased their price objective for the company from $24.00 to $35.00 in a research note on Tuesday, September 1st. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating and four have issued a buy rating to the company’s stock. Aimmune Therapeutics has a consensus rating of “Hold” and an average price target of $35.73.

Shares of NASDAQ:AIMT opened at $34.31 on Thursday. The stock’s 50-day moving average price is $20.03 and its two-hundred day moving average price is $17.56. The company has a current ratio of 7.53, a quick ratio of 7.40 and a debt-to-equity ratio of 0.73. Aimmune Therapeutics Inc has a 12-month low of $10.09 and a 12-month high of $37.00. The firm has a market cap of $2.25 billion, a price-to-earnings ratio of -7.64 and a beta of 1.71.

Aimmune Therapeutics (NASDAQ:AIMT) last issued its quarterly earnings results on Thursday, July 30th. The biotechnology company reported ($1.06) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($1.06). As a group, research analysts forecast that Aimmune Therapeutics Inc will post -4.35 earnings per share for the current fiscal year.

Aimmune Therapeutics Company Profile

Aimmune Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy.

Featured Article: What is a good rate of return for a mutual fund?

Want to see what other hedge funds are holding AIMT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aimmune Therapeutics Inc (NASDAQ:AIMT).

Institutional Ownership by Quarter for Aimmune Therapeutics (NASDAQ:AIMT)

Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.